|
|
Article: Dendreon Corporation Presents Provenge Data at Prostate Cancer Foundation Meeting.
- Article from:
- Business Wire
- Article date:
- November 10, 2003
CopyrightCOPYRIGHT 2003 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
BIOWIRE2K
SEATTLE--(BUSINESS WIRE)--Nov. 10, 2003
Dendreon Corporation (NASDAQ:DNDN) announced that it presented previously reported data from the completed Phase 3 trial of its investigational immunotherapy Provenge(R) for the treatment of androgen independent prostate cancer at the Prostate Cancer Foundation (formerly CaP CURE) 10th Annual Scientific Retreat taking place in New York City on November 8 -10, 2003. The conference gathers scientific thought leaders in prostate cancer research for a review and discussion of the latest clinical data, new discoveries and emerging treatment strategies.
...